Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer

Title:Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer

Volume: 24 Issue: 23

Author(s): Reyhaneh Moradi-Marjaneh, Majid Khazaei, Sima Seifi, Seyed Mahdi Hassanian, Gordon A. Ferns and Amir Avan*

Affiliation:

• Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran

Keywords: Colorectal cancer, polymorphisms, anticancer drugs, pharmacogenetics, gene polymorphisms, single nucleotide polymorphisms.

Abstract: Inter-individual differences in drug response are an important cause of failure in anticancer treatment and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been investigated in an effort to find new genetic biomarkers to predict toxicity and response to anticancer drugs. Evaluating the value single nucleotide polymorphisms (SNPs) in the genes involved in transportation, activation and metabolism of anticancer drugs provides a promising approach to select the appropriate therapeutic regimes with at least adverse reactions. This review summarizes the current knowledge about the relationship between of SNPs involved in the transportation, activation and metabolism of anticancer drugs and treatment outcomes in colorectal cancer (CRC) patients.

Cite this article as:

Moradi-Marjaneh Reyhaneh , Khazaei Majid , Seifi Sima , Hassanian Mahdi Seyed , Ferns A. Gordon and Avan Amir *, Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180727144535